Therapy for MS Archive - Page 3 of 6

Bei Multipler Sklerose helfen Medikamente. Die können aber auch Nebenwirkungen haben.

Side Effect of MS Medications: Dimethyl Fumarate

10. June 2022 Prof. Dr. med. Mathias Mäurer Therapy for MS

Dimethyl fumarate is marketed in Germany under the trade name Tecfidera® by the company Biogen, but is now also available generically (see MS-Docblog). Dimethyl fumarate is approved for the treatment of relapsing multiple sclerosis in

Generics in MS Therapy

31. May 2022 Prof. Dr. med. Mathias Mäurer Therapy for MS

In many diseases, the use of so-called generics is quite normal. In the therapy of MS, their use is (still) unusual. Because so far most MS drugs were patent-protected and therefore only original preparations were

Discontinue therapy?

16. May 2022 Prof. Dr. med. Mathias Mäurer Therapy for MS

I recently saw a 30-year-old patient in my office who was diagnosed with relapsing multiple sclerosis in 2016. She was put on PEGylated interferon-beta 1a due to moderate disease activity. Since then, no clinical relapses

Side Effect of MS Therapies: Teriflunomide

25. April 2022 Prof. Dr. med. Mathias Mäurer Therapy for MS

In addition to the effects of a substance, its side effects play an important role not only in the decision for therapy, but also in the practical application of MS therapy. This article is about

Side Effects of MS Therapies: Glatiramer Acetate

8. April 2022 Prof. Dr. med. Mathias Mäurer Therapy for MS

In addition to the effects of a substance, its side effects play an important role not only in the decision-making process for therapy, but also in the practical application of MS therapy. Therefore, the MS-Docblog

The Biomarker Serum Neurofilament Light Chains – Some Explanations and Statement on the New Study from Basel

7. March 2022 Prof. Dr. med. Mathias Mäurer Therapy for MS

Currently, both the medical professional press and the lay press are discussing the importance of the so-called Serum Neurofilament Light Chain value (abbreviation: sNfL). This is mainly due to a new study that was recently

Multiple Sclerosis in Children – Therapy (2)

17. December 2021 Prof. Dr. med. Mathias Mäurer Therapy for MS

The data and facts on pediatric MS show that consistent immunotherapy is indicated even in childhood to control the further course of the disease. This is contrasted by the fact that most MS therapies approved

Manche Wirkstoffe werden per Infusion gegeben.

ECTRIMS 2021 (4): When to stop therapy, when to extend the interval?

28. October 2021 Prof. Dr. med. Mathias Mäurer Therapy for MS

How long should immunotherapy for MS be continued? When can therapy be stopped? These are questions that not only concern MS patients but also many neurologists. Of course, one can take the position that long-lasting

High-Dose Biotin is a Dead End

2. July 2021 Prof. Dr. med. Mathias Mäurer Therapy for MS

The treatment options for progressive MS are limited – so interest was high when the study data on the use of high-dose biotin in progressive MS was first presented at the American Neurology Congress in

Pharmacovigilance Data on Ocrelizumab

20. July 2020 Prof. Dr. med. Mathias Mäurer Therapy for MS

In view of a number of inquiries, I assume that a work recently published in the journal Multiple Sclerosis and Related Disorders (MSARD) has caused some confusion. The work deals with the occurrence of COVID-19

Category: Therapy for MS

Side Effect of MS Medications: Dimethyl Fumarate

Generics in MS Therapy

Discontinue therapy?

Side Effect of MS Therapies: Teriflunomide

Side Effects of MS Therapies: Glatiramer Acetate

The Biomarker Serum Neurofilament Light Chains – Some Explanations and Statement on the New Study from Basel

Multiple Sclerosis in Children – Therapy (2)

ECTRIMS 2021 (4): When to stop therapy, when to extend the interval?

High-Dose Biotin is a Dead End

Pharmacovigilance Data on Ocrelizumab

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community